List of works - Jonas Cicenas

Highlights of the Latest Advances in Research on CDK Inhibitors.

scientific article

Increased Level of Phosphorylated ShcA Measured by Chemiluminescence-Linked Immunoassay Is a Predictor of Good Prognosis in Primary Breast Cancer Expressing Low Levels of Estrogen Receptor

scientific article published on 12 March 2010

Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2.

scientific article

JNK, p38, ERK, and SGK1 Inhibitors in Cancer.

scientific article published on 21 December 2017

KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma

scientific article published on 10 January 2017

Kinases and cancer

scientific article published in March 2018

Molecular modeling and structure-based drug discovery approach reveals protein kinases as off-targets for novel anticancer drug RH1.

scientific article

Non-Coding RNAs in Glioma

scientific article published on 22 December 2018

Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients.

scientific article

Protein chip based miniaturized assay for the simultaneous quantitative monitoring of cancer biomarkers in tissue extracts.

scientific article published in March 2006

Proteomic Analysis of Breast Cancer Resistance to the Anticancer Drug RH1 Reveals the Importance of Cancer Stem Cells

scientific article published on 11 July 2019

Proteomic Identification of FLT3 and PCBP3 as Potential Prognostic Biomarkers for Pancreatic Cancer

scientific article published on 01 October 2018

Quantitative proteomic analysis of anticancer drug RH1 resistance in liver carcinoma

scientific article published on 17 November 2015

Roscovitine in cancer and other diseases

scientific article

The CDK inhibitors in cancer research and therapy.

scientific article published on 30 August 2011

The expression of cancer stem cell markers in human colorectal carcinoma cells in a microenvironment dependent manner.

scientific article published on 4 February 2017

List of works by Jonas Cicenas

Highlights of the Latest Advances in Research on CDK Inhibitors.

Increased Level of Phosphorylated ShcA Measured by Chemiluminescence-Linked Immunoassay Is a Predictor of Good Prognosis in Primary Breast Cancer Expressing Low Levels of Estrogen Receptor

Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2.

JNK, p38, ERK, and SGK1 Inhibitors in Cancer.

KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma

Kinases and cancer

Molecular modeling and structure-based drug discovery approach reveals protein kinases as off-targets for novel anticancer drug RH1.

Non-Coding RNAs in Glioma

Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients.

Protein chip based miniaturized assay for the simultaneous quantitative monitoring of cancer biomarkers in tissue extracts.

Proteomic Analysis of Breast Cancer Resistance to the Anticancer Drug RH1 Reveals the Importance of Cancer Stem Cells

Proteomic Identification of FLT3 and PCBP3 as Potential Prognostic Biomarkers for Pancreatic Cancer

Quantitative proteomic analysis of anticancer drug RH1 resistance in liver carcinoma

Roscovitine in cancer and other diseases

The CDK inhibitors in cancer research and therapy.

The expression of cancer stem cell markers in human colorectal carcinoma cells in a microenvironment dependent manner.